Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.

Every business will reach inflection points where change is inevitable. Failure to change at these points may cause your business to lose momentum and die. Although there is no “wrong” time to ...

We're continuing to track the big tax and spending bill winding its way through Congress, which would add $2.4 trillion to the U.S. government deficit over 10 years, according to the nonpartisan ...

The last month felt like a year. Halfway through the first earnings season of 2026, and markets have already experienced two volatility spikes. 1 The first followed the nomination of Kevin Warsh as ...